Amelia Case
Family · Maynardville, TNNPI 1942507603
Payments from drug & device makers
Across 334 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$953
- Pfizer$613
- GSK$566
- Otsuka America Pharmaceutical, Inc.$452
- Novo Nordisk$408
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$289
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,983100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 71 | $953 |
| Pfizer | 38 | $613 |
| GSK | 37 | $566 |
| Otsuka America Pharmaceutical, Inc. | 18 | $452 |
| Novo Nordisk | 22 | $408 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $289 |
| Boehringer Ingelheim | 16 | $246 |
| AstraZeneca | 12 | $226 |
| Lilly USA, LLC | 13 | $212 |
| Abbott | 12 | $190 |
| Medtronic | 1 | $158 |
| Boston Scientific | 1 | $146 |
| Antares Pharma, Inc. | 1 | $129 |
| Lundbeck LLC | 6 | $122 |
| Novartis | 8 | $112 |
| Merck | 6 | $109 |
| Alkermes, Inc. | 6 | $103 |
| Axsome Therapeutics, Inc. | 6 | $97 |
| Phathom Pharmaceuticals, Inc. | 4 | $95 |
| Johnson & Johnson | 5 | $92 |
| Dexcom, Inc. | 5 | $92 |
| Idorsia Pharmaceuticals US Inc | 4 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $80 |
| Bayer | 4 | $67 |
| Exact Sciences | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Eisai Inc. | 2 | $29 |
| Amgen | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENDURANT IIS$158
- WATCHMAN FLX$146
- XYOSTED$129
- REXULTI$122
How this compares
$5,983 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $87,821 |
| VraylarCariprazine Hcl | 50 | $75,730 |
| MounjaroTirzepatide | 43 | $64,885 |
| OzempicSemaglutide | 40 | $62,061 |
| EliquisApixaban | 53 | $58,637 |
| RexultiBrexpiprazole | 30 | $42,295 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $35,279 |
| JardianceEmpagliflozin | 25 | $32,063 |
| Nurtec OdtRimegepant Sulfate | 17 | $25,245 |
| BelsomraSuvorexant | 49 | $24,687 |
| ProliaDenosumab | 12 | $21,002 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $19,017 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $18,607 |
| XareltoRivaroxaban | 21 | $16,381 |
| LinzessLinaclotide | 26 | $14,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $566 | $93,341105 claims |
| AbbVieVraylar, Linzess, Synthroid | $953 | $91,96790 claims |
| PfizerEliquis, Nurtec Odt | $613 | $83,88270 claims |
| Lilly USA, LLCMounjaro | $212 | $64,88543 claims |
| Novo NordiskOzempic | $408 | $62,06140 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $246 | $50,67038 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $452 | $42,29530 claims |
| AstraZenecaBreztri Aerosphere | $226 | $35,27931 claims |
| MerckBelsomra | $109 | $24,68749 claims |
| AmgenProlia | $29 | $21,00212 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $30 | $19,01717 claims |
| Johnson & JohnsonXarelto | $92 | $16,38121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Maynardville
- Jennifer SavageMaynardville$20K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.